Targeting vascular endothelial growth factor in renal cell carcinoma. by Patel, N, Muneer, A, Blick, C, Arya, M, Harris, A

“…Renal cancer is the most lethal of all urological malignancies with overall 5-year survival rates of around 60%. …”

24 YEARS OF RENAL CELL CARCINOMA NEPHRECTOMIES IN OXFORD, UK (1983-2007) by Charlesworth, P, Protheroe, A, Turner, G, Roberts, I, Harris, A, Cranston, D

Hypoxia and angiogenesis in primary clear cell renal carcinoma and its effect on patient prognosis by Charlesworth, P, Turner, G, Crew, J, Cranston, D, Protheroe, A, Harris, A

Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. by Braybrooke, J, Vallis, K, Houlbrook, S, Rockett, H, Ellmén, J, Anttila, M, Ganesan, T, Harris, A, Talbot, D

“…PURPOSE: Expression of P-glycoprotein (Pgp), which confers the multidrug resistance (MDR) phenotype, is thought to contribute to the insensitivity of renal cell cancer (RCC) to chemotherapy. The development of Pgp inhibitors for clinical application has been hampered by unacceptable toxicity at doses required to achieve adequate cellular concentration. …”

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. by Deplanque, G, Madhusudan, S, Jones, P, Wellmann, S, Christodoulos, K, Talbot, D, Ganesan, T, Blann, A, Harris, A

“…The high vascularity and responsiveness to immunotherapy of renal cell carcinoma (RCC) makes such a tumour a potential target for IM862. …”

Changing prognosis of renal cell carcinoma: A single-centre experience over 25 years by Charlesworth, P, Sullivan, M, Protheroe, A, Turner, G, Roberts, I, Kilbey, N, Harris, A, Cranston, D

“…Objective: The objective of this research is to examine renal cancer nephrectomies over 25 years in our centre andthe factors underlying changes in disease-specific survival. …”

Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. by Turner, K, Moore, J, Jones, A, Taylor, C, Cuthbert-Heavens, D, Han, C, Leek, R, Gatter, K, Maxwell, P, Ratcliffe, P, Cranston, D, Harris, A

“…Mutations of the von Hippel-Lindau tumor suppressor protein are found in most clear cell renal cell carcinomas (CC-RCCs) but not other renal tumors, raising a question about the importance of activation of the HIF pathway in CC-RCC development. …”

Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion by Hornigold, N, Dunn, KR, Craven, RA, Zougman, A, Trainor, S, Shreeve, R, Brown, J, Sewell, H, Shires, M, Knowles, M, Fukuwatari, T, Maher, ER, Burns, J, Bhattarai, S, Menon, M, Brazma, A, Scelo, G, Feulner, L, Riazalhosseini, Y, Lathrop, M, Harris, A, Selby, PJ, Banks, RE, Vasudev, NS

“…</p> <p><strong>Methods</strong></p> <p>Matched renal cell carcinoma (RCC) and normal kidney tissues were subject to proteomic profiling. …”

CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. by Adam, P, Terrett, J, Steers, G, Stockwin, L, Loader, J, Fletcher, G, Lu, L, Leach, B, Mason, S, Stamps, A, Boyd, R, Pezzella, F, Gatter, K, Harris, A

“…In order to identify potential markers of renal cancer, the plasma membrane protein content of renal cell carcinoma (RCC)-derived cell lines was annotated using a proteomics process. …”

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. by Raval, R, Lau, K, Tran, MG, Sowter, H, Mandriota, S, Li, J, Pugh, C, Maxwell, P, Harris, A, Ratcliffe, P

“…Defective function of the von Hippel-Lindau (VHL) tumor suppressor ablates proteolytic regulation of hypoxia-inducible factor alpha subunits (HIF-1alpha and HIF-2alpha), leading to constitutive activation of hypoxia pathways in renal cell carcinoma (RCC). Here we report a comparative analysis of the functions of HIF-1alpha and HIF-2alpha in RCC and non-RCC cells. …”

miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. by McCormick, R, Blick, C, Ragoussis, J, Schoedel, J, Mole, D, Young, A, Selby, P, Banks, R, Harris, A

“…MicroRNA-210 is upregulated in renal cancer compared with normal renal cortex tissue. …”

The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. by Nikitenko, L, Leek, R, Henderson, S, Pillay, N, Turley, H, Generali, D, Gunningham, S, Morrin, H, Pellagatti, A, Rees, M, Harris, A, Fox, S

“…We therefore investigated the diagnostic/prognostic use for CLR in human tumor types that may rely on adrenomedullin signaling and in clear cell renal cell carcinoma (RCC), a highly vascular tumor, in particular. …”

MiR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis by McCormick, R, McCormick, R, Blick, C, Ragoussis, J, Schoedel, J, Mole, DR, Young, A, Selby, P, Banks, R, Harris, A

“…MicroRNA-210 is upregulated in renal cancer compared with normal renal cortex tissue. …”

Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts. by Biswas, S, Troy, H, Leek, R, Chung, Y, Li, J, Raval, R, Turley, H, Gatter, K, Pezzella, F, Griffiths, JR, Stubbs, M, Harris, A

“…In cultured clear-cell renal carcinoma (CCRCC) 786-0 cells transfected with HIF1alpha (HIF-1+), HIF-2alpha (HIF-2+), or empty vector (EV), no significant differences were observed in the growth rates in vitro, but when grown in vivo as xenografts HIF-2alpha significantly increased, and HIF-1alpha significantly decreased growth rates, compared to EV tumors. …”

RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition PONE-D-17-28641 by Earwa, P, Anderson, C, Willenbrock, F, Harris, A, Protheroe, A, Macaulay, V

“…The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. …”

CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC. by Biswas, S, Charlesworth, P, Turner, G, Leek, R, Thamboo, P, Campo, L, Turley, H, Dildey, P, Protheroe, A, Cranston, D, Gatter, K, Pezzella, F, Harris, A

“…Hypoxia-inducible factors, HIF-1α and HIF-2α, are expressed in the majority of clear-cell renal cell carcinoma (CC-RCC). In vitro, HIFα isoforms regulate a differential set of genes, and their effects in vivo within CC-RCC tumours may affect outcome. …”

The Role of Hypoxia-Regulated MicroRNA in Cancer by McCormick, R, Robert McCormick

“…The expression of hypoxia-regulated miRNAs was examined in clinical renal tumour samples with matched normal tissue controls, and correlated with VHL mutation status.…”

Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. by Wykoff, C, Sotiriou, C, Cockman, M, Ratcliffe, P, Maxwell, P, Liu, E, Harris, A

“…Gene expression analysis was performed on a human renal cancer cell line (786-0) with mutated VHL gene and a transfectant with wild-type VHL to analyse genes regulated by VHL and to compare with the gene programme regulated by hypoxia. …”

Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. by Bardella, C, El-Bahrawy, M, Frizzell, N, Adam, J, Ternette, N, Hatipoglu, E, Howarth, K, O'Flaherty, L, Roberts, I, Turner, G, Taylor, J, Giaslakiotis, K, Macaulay, V, Harris, A, Chandra, A, Lehtonen, H, Launonen, V, Aaltonen, L, Pugh, C, Mihai, R, Trudgian, D, Kessler, B, Baynes, J, Ratcliffe, P, Tomlinson, I

“…Germline mutations in the FH gene encoding the Krebs cycle enzyme fumarate hydratase predispose to hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. FH-deficient cells and tissues accumulate high levels of fumarate, which may act as an oncometabolite and contribute to tumourigenesis. …”

Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. by Bardella, C, El-Bahrawy, M, Frizzell, N, Adam, J, Ternette, N, Hatipoglu, E, Howarth, K, O'Flaherty, L, Roberts, I, Turner, G, Taylor, J, Giaslakiotis, K, Macaulay, V, Harris, A, Chandra, A, Lehtonen, H, Launonen, V, Aaltonen, L, Pugh, C, Mihai, R, Trudgian, D, Kessler, B, Baynes, J, Ratcliffe, P, Tomlinson, I, Pollard, P

“…Germline mutations in the FH gene encoding the Krebs cycle enzyme fumarate hydratase predispose to hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. FH-deficient cells and tissues accumulate high levels of fumarate, which may act as an oncometabolite and contribute to tumourigenesis. …”